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vious history of cardiovascular disease or equivalent was sub-
stantially higher (p < 0.001) for those treated with atorvastatin
(53.54%) than for those treated with any other statin; lovastatin:
29.49%; simvastatin: 42.58%; pravastatin: 52%; ﬂuvastatin:
41.1%; 2) Atorvastatin was used in patients with a signiﬁcantly
higher number of CVRF (2) than that of lovastatin: 1.7; 
simvastatin: 1.8; pravastatin: 1.9 and ﬂuvastatin: 1.8 (p <
0.0001); and 3) the use of Atorvastatin with a higher proportion
of subjects under optimal cLDL control in comparison with all
the other statins as a group (52.8% vs. 46.47%; p < 0.01) and
individually considered (lovastatin 50.7%; simvastatin 41.3%;
pravastatin 43%; atorvastatin 52.8%; ﬂuvastatin 39%). CON-
CLUSIONS: In daily clinical practice in Spain, atorvastatin is
used in patients with more cardiovascular risk factors and worse
risk proﬁle, in comparison with other commercialized statins,
however, treatment with atorvastatin is related with a higher pro-
portion of patients with appropriate control of cLDL as per ATP
III criteria. Even in a high quality environment, there is room for
improving the average proportion with appropriate control of
CVRF.
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OBJECTIVE: To determine cardiovascular risk factors proﬁle
(CVRF) and the percentage of patients reaching goals as deﬁned
by ATP III, in a population of patients with dyslipidemia and/or
hypertension, in daily clinical practice. METHODS: A total of
9001 patients with dyslipidemia and/or hypertension, assigned
to four Catalan primary care centres were selected. 1) CVRF
proﬁle; 2) a classiﬁcation of the patients by LDL cholesterol
(cLDL) levels, as for the ATP III criteria; and 3) the percentage
of patients reaching optimal control goals, were estimated for
the three groups: hypertensives without dyslipidemia (HT
without DL), patients with dyslipidemia without HT (DL
without HT) and hypertensives with dyslipidemia (HT with DL).
RESULTS: 1) Cardiovascular heart disease or equivalent was
present in 36.8%. A 7.9% had one CVRF; 29.2% two CVRF;
43.2% three CVRF; 17.1% four CVRF and 2.1% ﬁve CVRF. 2)
Percentage with opitmal cLDL control was 40.1% for HT
without DL, 29.6% for DL without HT and 27.8% for HT with
DL. 3) A 27.1% simultaneously had optimal levels of cLDL and
blood pressure (BP). That percentage was 30.1% for HT without
DL; 27.5% for DL without HT and 21.9% for DL with HT (p
< 0.0001). CONCLUSIONS: More than one-third (36.8%) of
patients with hypertension and/or dyslipidemia have a previous
history of cardiovascular disease or equivalent. Almost two-
thirds (62.9%) presented with one or more additional CVRF.
Despite high quality standards, the proportion of patients with
optimal levels of cLDL and BP (27.1%) is small and there is
much room for improvement.
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OBJECTIVE: To assess costs related to hypertension in the
elderly and in patients less than 65 years of age with uncontrolled
hypertension in Poland. METHODS: The time horizon of the
analysis was 12 months and a retrospective approach was
applied. Calculations were made from the societal perspective
and third party payer perspective. Both direct medical costs and
indirect costs were included. A detailed cost analysis was made
for the 4392 patients with uncontrolled hypertension, compar-
ing elderly patients with patients under 65. Resource utilisation
data were derived from a scientiﬁc project conducted among GPs
in the whole of Poland in the year 2000. Data concerning the
efﬁciency of blood pressure control were gathered from the
Polish epidemiological study. Unit costs were obtained from 
the Polish National Health Fund. RESULTS: Among the 8.4
million hypertensive patients in Poland 57% receive active treat-
ment, 80% (3.8 million) of which do not reach the appropriate
blood pressure target. The distribution of the direct medical costs
in patients with uncontrolled hypertension was as follows: drugs
29%, laboratory, diagnostic tests 13%, hospitalisation 27% and
physicians’ consultations 31%. Taking the societal perspective,
the direct medical costs were higher by 8% in the elderly uncon-
trolled patients and amounted to €249.30 but indirect costs were
more than 12 times lower in the elderly as compared to €241.85
in patients under 65. The total costs in the elderly uncontrolled
patients assessed from the third party payer perspective were
higher by 14% and amounted to €201.74. CONCLUSION: The
costs related to uncontrolled hypertension constitute a consider-
able economic burden. Uncontrolled hypertension might be the
cause of increasing expenditure on health care in the near future.
Wider use of more efﬁcient antihypertensive drugs may help to
avoid this phenomenon.
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OBJECTIVE: To compare costs in patients with non-
complicated arterial hypertension to costs in hypertensive
patients suffering from concomitant diseases in Poland.
METHODS: The time horizon of the analysis was 12 months
and a retrospective approach was applied. Calculations were
made from the societal perspective and third party payer per-
spective. Both direct medical and indirect costs were included.
Costs in patients (n = 2532) with non-complicated hypertension
were compared to costs observed in hypertensive patients (n =
2702) with co-existing: hypercholesterolemia, diabetes mellitus,
coronary artery disease, heart failure and a combination of these.
Resource utilisation data were derived from a scientiﬁc project
conducted among GPs in the whole of Poland in the year 2000.
The unit costs were obtained from the Polish National Health
Fund. RESULTS: The annual direct medical costs in a patient
with non-complicated hypertension amounted to €184.12. The
costs increase observed in a patient with concomitant disease was
as follows: 5% in diabetes mellitus, 6% in hypercholesterolemia,
16% in heart failure, and 19% in coronary artery disease. The
highest cost increase was related to hypertensive patients suffer-
ing from coronary artery disease co-existing with diabetes (63%)
and heart failure (80%). The costs of hospitalisation and
doctors’ consultations were identiﬁed as crucial cost drivers in
all evaluated groups. The indirect costs contribution in the total
costs was the highest (57%) in the coronary artery disease group
and the lowest (26%) in the diabetes group and it respectively
amounted to €288.26 and €68.49 per patient per year respec-
tively, in comparison with €128.87 in the group with non-
complicated hypertension. CONCLUSION: A wider use of anti-
hypertensive drugs more effective in terms of blood pressure
